Sexually transmitted diseases (STDs) are a major worldwide health problem that compromise reproductive fecundity as well as cut short the lives of millions of men, women and children.1,2 Despite extensive efforts, only limited success has been achieved in dealing with STDs, including herpes simplex virus type 2 (HSV-2), Chlamydia trachomatis, group B streptococcus and human immunodeficiency virus [(HIV), the causative agent of acquired immune-deficiency syndrome (AIDS)],3 which collectively devastate both adults and newborns. It is now well recognized that the heterosexual transmission of HIV, which is reponsible for 70–80% of the new cases identified in the last 2 years, is the major route of infection worldwide.4,5 With the identification of HIV in semen and cervical secretions,6–8 AIDS is now the major life-threatening STD.9,10 As strategies are developed to prevent and effectively treat this growing global health problem, understanding the immune system in the female reproductive tract and the way it is regulated by the endocrine system has particular importance.

The adaptive and innate immune systems are the two key branches that determine host protection throughout the female reproductive tract and at other mucosal surfaces, including the respiratory, gastrointestinal and urinary tracts. Adaptive immunity encompasses the recognition and response to antigens with resultant protection that is gradual, very specific and mediated through antibodies and/or T cells. In contrast, innate immune responses use non-specific mechanisms that are inherent, rapid and mediated by germline-encoded receptors.11 Our understanding of the innate immune system is a result, in large part, of the pioneering studies of Charles Janeway, who demonstrated that innate immunity covers many areas of host defence against pathogenic microbes.12 During the last decade, investigations of the innate immune system have shown that microbial pathogens are recognized by Toll-like receptors that, in turn, regulate the activation of both innate and adaptive immunity.11

Mucosal surfaces have evolved to handle potential pathogens against a background of selective physiological functions. In the reproductive tract, the immune system must balance the presence of a resident population of bacteria in the vagina with periodic exposure in the uterus and Fallopian tubes of antigens (bacteria and sperm), as well as the long-term exposure of an allogeneic fetus. Failure of the immune system either to rid the reproductive tract of potential pathogens or to resist attacking allogeneic sperm and fetus significantly compromises procreation, as well as the health of the mother. To meet these diverse challenges, the immune system has evolved to be precisely regulated by the ovarian hormones oestradiol and progesterone, which prepare the reproductive tract for successful fertilization, implantation and pregnancy.

In the current issue of Immunology, the article by MacNeill et al.13 collectively extends our understanding of the complexity of the innate immune system that has evolved to confer protection against potential pathogens. Previous studies have demonstrated the essential role of Surfactant protein A (SP-A), a member of the collectin family of proteins, in protecting the respiratory system from infections. SP-A gene knockout mice are more susceptible to bacterial and viral lung infections than their wild-type counterparts.14 The findings of MacNeill et al., that SP-A is expressed in the vagina, demonstrates the existence of a new molecule in the reproductive tract that is important in host defence. As discussed in their article, SP-A has the ability to facilitate phagocytosis of micro-organisms, stimulate chemotaxis, increase the oxidative burst by phagocytes and modulate pro-inflammatory cytokine production by immune cells.15–17 Moreover, SP-A has been shown to regulate the differentiation and chemotaxis of monocytic cells, including dendritic cells, to provide a link between innate and adaptive immune responses.18 Of particular importance is the growing body of evidence demonstrating that SP-A binds to a diverse range of Gram-negative and Gram-positive bacterial and viral pathogens,19 providing for effective killing and/or opsonization by phagocytic cells.

Innate immunity utilizes a spectrum of molecules to confer protection against potential pathogens. One example is the production of soluble factors by female reproductive tract epithelial cells that inhibit the growth of micro-organisms. Among the epithelial cell secretions with known bactericidal effects are defensins, secretory leucocyte protease inhibitor (SLPI), the enzymes lysozyme and lactoferrin, as well as other antimicrobial peptides (reviewed in ref. 20). While research in a number of laboratories has demonstrated sex hormone regulation on multiple aspects of the adaptive immune system (reviewed in refs 21 and 22), we have only begun to explore the hormonal regulation of innate immunity in the female reproductive tract. What is clear is that epithelial cells from a variety of tissues produce defensins, particularly β-defensins.23 The synthesis and/or release of these ‘natural antibiotics’ may be constitutive or rapidly induced by infections or toxins, and, in general, they act via their amphiphilic charge on the microbial membrane to create pores or otherwise affect permeability. These ubiquitous antimicrobials are effective against Gram-negative and Gram-positive bacteria, fungi and some viruses. Human β-defensin 1 is produced by the epithelial cells of the female reproductive tract24 and has a primary role in defending mucosal surfaces against microbes.25 Human β-defensin 1 is primarily constitutively produced, whereas human β-defensin-2 is usually induced by infection. Zhao and colleagues25 suggested that human β-defensins have a primary role to defend epithelial cells and mucosal surfaces from microbes, while α-defensins function systemically to allow immune cells access to vascularized tissues.

Recent studies suggest that, as with the adaptive immune system in the female reproductive tract, some components of the innate immune system are under hormonal control. For example, the level of human defensin-5, an α-defensin produced by endometrial epithelial cells, is highest during the secretory stage (postovulatory) of the menstrual cycle.26 SLPI is produced by macrophages and epithelial cells, including those in the female reproductive tract,27 and has broad-spectrum activity against a variety of potential pathogens,28 including HIV-1.29,30 Levels and/or expression of SLPI vary in cervical mucus during the menstrual cycle (but not in serum)31,32 and increase in amniotic fluid during gestation. King and associates showed that the primary site of SLPI synthesis in the endometrium and decidua was the glandular epithelium, and tissues derived from women in the late secretory phase produced higher SLPI levels than tissues obtained from women in the proliferative phase.33 In our laboratory, polarized monolayers of uterine epithelial cells from premenopausal women secreted more SLPI than did cells from postmenopausal women.34 When bactericidal activity was analysed, Gram negative and Gram positive bacteria were inhibited by apical secretions from uterine epithelial cells. As antibacterial activity was neutralized by antibody specific for SLPI, the antibacterial activity demonstrated by the human uterine epithelial cells is probably a result of the presence of SLPI, the secretion of which is dependent on menstrual status.

In summary, understanding how the immune system in the reproductive tract responds to bacterial and viral challenges requires that we identify the unique characteristics of the immune system in the Fallopian tube, uterus, cervix and vagina, and the ways in which the innate and adaptive immune systems are either enhanced and/or suppressed by sex hormones at particular times in a woman's life. Studies like those of MacNeill et al.13 provide important new information that extends our knowledge of immune protection. These studies and others like it should provide the basis essential for the prevention of local infection in the genital mucosa and the management of sexually transmitted diseases.


  1. Top of page
  2. References
  • 1
    Cates W. Priorities for sexually transmitted diseases in the late 1980s and beyond. Sex Transm Dis 1986; 13 : 1147.
  • 2
    Piot P, Plummer FA, Mhalu FS, Lamboray JL, Chin J, Mann JM. AIDS. An international perspective. Science 1988; 239 : 5739.
  • 3
    Peterman TA, Curran JW. Sexual transmission of human immunodeficiency virus. JAMA 1986; 256 : 22226.
  • 4
    Harris C, Small CB, Klein RS, Friedland GH, Moll B, Emeson EE, Spigland I, Steigbigel NH. Immunodeficiency in female sexual partners of men with the acquired immunodeficiency syndrome. N Engl J Med 1983; 308 : 11814.
  • 5
    Calabrese LH, Gopalakrishna KV. Transmission of HTLV-III infection from man to woman to man. N Engl J Med 1986; 314 : 987.
  • 6
    Ho DD, Schooley RT, Rota TR, Kaplan JC, Flynn T, Salahuddin SZ, Gonda MA, Hirsh MS. HTLV-III in the semen and blood of a healthy homosexual man. Science 1984; 226 : 4513.
  • 7
    Vogt MW, Craven DE, Crawford D, Witt D, Byington R, Schooley R, Hirsch MS. Isolation of HTLV-III from cervical secretions of woman at risk for AIDS. Lancet 1986; I : 5257.
  • 8
    Wofsy CB, Cohen JB, Hauer LB, Padian NS, Michaelis BA, Evans LA, Levy JA. Isolation of AIDS-associated retrovirus from genital secretions of women with antibodies to the virus. Lancet 1986; 1 : 5279.
  • 9
    McDonough PG. Comment. Fert Steril 1987; 48 : 704.
  • 10
    Alexander NJ, Anderson DJ. Immunology of semen. Fert Steril 1987; 47 : 192205.
  • 11
    Janeway CAJ, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20 : 197216.
  • 12
    Janeway CAJ. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989; 54 : 113.
  • 13
    MacNeill C, Umstead TM, Phelps DS, Lin Z, Floros J, Shearer DA, Weisz J. Surfactant protein-A, an innate immune factor, is expressed in the vaginal mucosa and is present in vaginal lavage fluid. Immunology 2004; 111 : 99107.
  • 14
    LeVine AM, Whitsett JA. Pulmonary collectins and innate host defense of the lungs. Microbes Infect 2001; 3 : 16166.
  • 15
    Crouch E, Wright JR. Surfactant proteins a and d and pulmonary host defense. Annu Rev Physiol 2001; 63 : 52154.
  • 16
    Phelps DS. Surfactant regulation of host defense function in the lung: a question of balance. Pediatr Pathol Mol Med 2001; 20 : 26992.
  • 17
    LeVine AM, Whitsett JA, Gwozdz JA, Richardson TR, Fisher JH, Burhans MS, Korfhagen TR. Distinct effects of surfactant protein A or D deficiency during bacterial infection on the lung. J Immunol 2000; 165 : 393440.
  • 18
    Brinker KG, Garner H, Wright JR. Surfactant protein A modulates the differentiation of murine bone marrow-derived dendritic cells. Am J Physiol Lung Cell Mol Physiol 2003; 284 : L23241.
  • 19
    Lawson PR, Reid KBM. Role of surfactant proteins A and D in innate immunity. Immunol Rev 2000; 173 : 6678.
  • 20
    Ganz T. Defensins and host defense. Science 1999; 286 : 4201.
  • 21
    Wira CR, Crane-Godreau M, Grant K. Endocrine regulation of the mucosal immune system in the female reproductive tract. In: OgraPL, MesteckyJ, LammME, StroberW, McGheeJR, BienenstockJ, eds. Mucosal Immunology. San Diego, CA: Elsevier Inc., 2004: in press.
  • 22
    Wira CR, Fahey J, White HD, Yeaman GR, Given A, Howell A. The mucosal immune system in the human female reproductive tract: influence of stage of the menstrual cycle and menopause on mucosal immunity in the uterus. In: GlasserS, AplinJ, GuidiceL, TabibzadehS (eds). The Endometrium. New York: Taylor & Francis, 2002: 371404.
  • 23
    Stolzenberg ED, Anderson GM, Ackermann MR, Whitlock RH, Zasloff M. Epithelial antibiotic induced in states of disease. Proc Natl Acad Sci USA 1997; 94 : 868690.
  • 24
    Valore EV, Park CH, Quayle AJ, Wiles KR, McCray PB Jr, Ganz T. Human β-defensin 1, an antimicrobial peptide of urogenital tissues. J Clin Invest 1998; 101 : 163342.
  • 25
    Zhao CQ, Wang I, Lehrer RI. Widespread expression of beta-defensin HBD-1 in human secretory glands and epithelial cells. FEBS Lett 1996; 396 : 31922.
  • 26
    Quayle AJ, Martin Porter E, Nussbaum AA, Wang YM, Brabec C, Yip K-P, Mok SC. Gene expression, immunolocalization and secretion of human defensin-5 in human female reproductive tract. Am J Pathol 1998; 152 : 124758.
  • 27
    Fichorova RN, Anderson DJ. Differential expression of immunobiological mediators by immortalized human cervical and vaginal epithelial cells. Biol Reprod 1999; 60 : 50814.
  • 28
    Hiemstra PS, Maassen RJ, Stolk J, Heinzel-Wieland R, Steffens GJ, Dijkman JH. Antibacterial activity of antileukoprotease. Infect Immun 1996; 64 : 45204.
  • 29
    McNeely T, Shugars D, Rosendahl M, Tucker C, Eisenberg S, Wahl S. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 1997; 90 : 11419.
  • 30
    Wahl S, McNeely T, Janoff E, Shugars DC, Worley P, Tucker C, Orenstein JM. Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-1. Oral Dis 1997; 3 (Suppl. 1):S649.
  • 31
    Moriyama A, Shimoya K, Ogata I et al. Secretory leukocyte protease inhibitor (SLPI) concentrations in cervical mucus of women with normal menstrual cycle. Mol Human Reprod 1999; 5 : 65661.
  • 32
    Draper D, Landers D, Krohn M, Hillier S, Weisenfeld H, Heine R. Levels of vaginal secretory leukocyte protease inhibitor are decreased in women with lower reproductive tract infections. Am J Obstet Gynecol 2000; 183 : 12438.
  • 33
    King AE, Critchley HOD, Kelly RW. Presence of secretory leukocyte protease inhibitor in human endometrium and first trimester decidua suggests an antibacterial protective role. Mol Human Reprod 2000; 6 : 1916.
  • 34
    Fahey JV, Wira CR. Effect of menstrual status on anti-bacterial activity and secretory leukocyte protease inhibitor production by human uterine epithelial cells in culture. J Infect Dis 2002; 185 : 160613.